To analyze and compare the clinical efficacy and safety of irinotecan chemotherapy regimen and irinotecan combined with ubenimex chemotherapy regimen for the treatment of advanced gastric cancer.

The clinical data of 104 patients with advanced gastric cancer admitted to Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology from January 2018 to January 2022 were retrospectively analyzed.According to the different treatment plans adopted by the patients, all the patients were divided into control group(irinotecan chemotherapy plan, n=61)and observation group(irinotecan combined with ubenimex treatment plan, n=43), and were treated with 21 days as 1 cycle for a total of 2 Cycle.The short-term clinical efficacy of the two groups at 1 week after treatment, the levels of CD3+, CD4+, CD4+ /CD8+ in the peripheral blood before and after treatment, the quality of life after treatment, the survival within 1 year after the end of treatment, and the incidence of adverse reactions during treatment were compared.

One week after the end of treatment, the partial response(PR), objective response rate(ORR)and disease control rate(DCR)of patients in the observation group were significantly higher than those of patients in the control group(P<0.05), and the stable disease(SD)and progressive disease(PD)were significantly lower than those of patients in the control group(P<0.05). Before treatment, there were no statistically significant differences in the levels of CD3+, CD4+ and CD4+ /CD8+ in the peripheral blood of the two groups(P>0.05), but after treatment, the levels of CD3+, CD4+ and CD4+ /CD8+ in the peripheral blood of the two groups increased, and the observation group was higher than the control group(P<0.001). After treatment, patients in the observation group had significantly lower scores in the symptom domains of dysphagia and feeding restriction than those in the control group(P<0.05). During the 1-year follow-up, disease progression-free survival was significantly longer in the observation group than in the control group [(7.42±0.89)months vs.(5.35±0.68)months, P<0.001). Comparing the total incidence of adverse reactions during the treatment period between the two groups, there was no statistically significant difference(P>0.05).

The clinical efficacy of irinotecan combined with ubenimex in the treatment of advanced gastric cancer is more significant, which can improve the immunity function of the patients, improve the quality of life of the patients, prolong the progression-free survival time of the patients, with higher safety.